Brief: Valbiotis says Phase I/II Valedia study validate safety and first proof of efficacy

Valbiotis SA

09/06/2017 06:32

June 9 (Reuters) - VALBIOTIS SAS  ALVAL.PA  
    * WILL PRESENT RESULTS OF ITS PHASE I/II CLINICAL STUDY ON 
ACTIVE INGREDIENT OF VALEDIA, TOTUM-63 
    * RESULTS VALIDATE SAFETY AND A FIRST PROOF OF EFFICACY FOR 
VALEDIA 
 
Source text for Eikon:  ID:nBw8StHxla  
Further company coverage:  ALVAL.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))